Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHCNASDAQ:CNTANASDAQ:GLPGNASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Companies$4.53+4.3%$6.43$3.96▼$9.85$1.66B0.432.68 million shs2.36 million shsCNTACentessa Pharmaceuticals$11.94$15.19$7.75▼$19.09$1.59B1.53597,621 shs594,432 shsGLPGGalapagos$23.88-1.3%$25.28$22.36▼$31.23$1.57B0.16200,518 shs496,610 shsSTOKStoke Therapeutics$7.75+2.5%$8.07$5.35▼$17.58$419.10M1.09712,170 shs512,136 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Companies+4.50%-5.85%-36.67%-40.30%-47.60%CNTACentessa Pharmaceuticals0.00%+11.48%-30.34%-22.47%+10.76%GLPGGalapagos-1.32%+1.53%-8.19%+0.46%-19.87%STOKStoke Therapeutics+2.51%+31.36%-9.88%-18.34%-36.53%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHCBausch Health Companies4.0027 of 5 stars2.93.00.04.01.91.71.9CNTACentessa Pharmaceuticals2.925 of 5 stars3.53.00.00.02.53.30.6GLPGGalapagos0.6529 of 5 stars0.84.00.00.03.10.00.6STOKStoke Therapeutics3.2502 of 5 stars3.60.00.04.82.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Companies 1.86Reduce$7.1758.38% UpsideCNTACentessa Pharmaceuticals 3.00Buy$27.71132.11% UpsideGLPGGalapagos 1.50Reduce$25.336.09% UpsideSTOKStoke Therapeutics 3.13Buy$24.67218.28% UpsideCurrent Analyst Ratings BreakdownLatest STOK, GLPG, BHC, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/7/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform$9.00 ➝ $8.503/31/2025CNTACentessa PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$38.003/26/2025CNTACentessa PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/19/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$47.00 ➝ $47.003/19/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.003/18/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/7/2025CNTACentessa PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$27.00 ➝ $27.002/19/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.002/18/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $47.002/18/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Companies$9.63B0.17$4.81 per share0.94($0.89) per share-5.08CNTACentessa Pharmaceuticals$6.85M232.05N/AN/A$2.42 per share4.93GLPGGalapagos$275.65M5.71N/AN/A$47.57 per share0.50STOKStoke Therapeutics$36.56M11.47N/AN/A$3.57 per share2.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Companies-$46M-$0.12N/A0.970.37-0.48%-577.82%5.24%4/30/2025 (Estimated)CNTACentessa Pharmaceuticals-$151.09M-$1.99N/AN/AN/AN/A-52.13%-38.01%5/12/2025 (Estimated)GLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A4/23/2025 (Estimated)STOKStoke Therapeutics-$104.70M-$1.68N/AN/AN/A-629.90%-54.45%-40.77%5/5/2025 (Estimated)Latest STOK, GLPG, BHC, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35N/AN/AN/AN/AN/A5/5/2025Q1 2025STOKStoke Therapeutics-$0.42N/AN/AN/A$27.37 millionN/A4/30/2025Q1 2025BHCBausch Health Companies$1.46N/AN/AN/A$2.29 billionN/A4/23/2025Q1 2025GLPGGalapagos-$0.19N/AN/AN/A$72.22 millionN/A3/24/2025Q4 2024CNTACentessa Pharmaceuticals-$0.38-$0.34+$0.04-$0.84N/AN/A3/24/2025Q4 2024STOKStoke Therapeutics-$0.56-$0.18+$0.38-$0.18$4.20 million$22.61 million2/19/2025Q4 2024BHCBausch Health Companies$1.65$1.21-$0.44$0.25$2.51 billion$2.56 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CompaniesN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health CompaniesN/A0.860.62CNTACentessa Pharmaceuticals0.1521.5221.52GLPGGalapagosN/A9.979.81STOKStoke TherapeuticsN/A5.095.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Companies78.65%CNTACentessa Pharmaceuticals82.01%GLPGGalapagos32.46%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipBHCBausch Health Companies8.12%CNTACentessa Pharmaceuticals11.59%GLPGGalapagos2.91%STOKStoke Therapeutics11.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Companies19,900367.93 million338.06 millionOptionableCNTACentessa Pharmaceuticals200133.18 million116.56 millionOptionableGLPGGalapagos1,31065.90 million63.98 millionOptionableSTOKStoke Therapeutics10054.08 million46.98 millionOptionableSTOK, GLPG, BHC, and CNTA HeadlinesRecent News About These CompaniesStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from BrokeragesApril 16 at 2:15 AM | americanbankingnews.comWhy Stoke Therapeutics, Inc.’s (STOK) Stock Is Up 7.69%April 15 at 4:56 AM | aaii.comTrexquant Investment LP Sells 58,718 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)April 13 at 4:46 AM | marketbeat.com314,800 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Acquired by Norges BankApril 13 at 4:03 AM | marketbeat.comStoke Therapeutics' (STOK) "Buy" Rating Reiterated at Needham & Company LLCApril 12, 2025 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLCApril 11, 2025 | marketbeat.comNeedham Keeps Their Buy Rating on Stoke Therapeutics (STOK)April 10, 2025 | markets.businessinsider.comStoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | businesswire.comStoke Therapeutics remains significantly undervalued, says CanaccordApril 1, 2025 | markets.businessinsider.comWhat is Chardan Capital's Forecast for STOK FY2025 Earnings?March 28, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Forecast for STOK EarningsMarch 24, 2025 | marketbeat.comEarnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMarch 22, 2025 | finance.yahoo.comWhat is HC Wainwright's Forecast for STOK Q3 Earnings?March 22, 2025 | marketbeat.comLeerink Partnrs Weighs in on STOK Q1 EarningsMarch 22, 2025 | marketbeat.comQ1 EPS Estimate for Stoke Therapeutics Lifted by AnalystMarch 22, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by BrokeragesMarch 22, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 2,266 Shares of StockMarch 21, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells 3,884 Shares of StockMarch 21, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Sells 10,382 Shares of StockMarch 21, 2025 | marketbeat.comEquities Analysts Offer Predictions for STOK Q1 EarningsMarch 21, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan Sells 2,266 SharesMarch 21, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialRecession Risk: Is It Going to Happen? Here Are the Key CluesBy Jea Yu | March 26, 2025View Recession Risk: Is It Going to Happen? Here Are the Key CluesSTOK, GLPG, BHC, and CNTA Company DescriptionsBausch Health Companies NYSE:BHC$4.53 +0.19 (+4.26%) Closing price 04/15/2025 03:59 PM EasternExtended Trading$4.50 -0.02 (-0.44%) As of 04/15/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Centessa Pharmaceuticals NASDAQ:CNTA$11.94 0.00 (0.00%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$11.94 0.00 (0.00%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Galapagos NASDAQ:GLPG$23.88 -0.32 (-1.32%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$23.87 -0.01 (-0.04%) As of 04/15/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Stoke Therapeutics NASDAQ:STOK$7.75 +0.19 (+2.51%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$7.26 -0.49 (-6.32%) As of 04:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Congress! Who Traded What During the Tariff-Induced Meltdown Beware of BigBear.ai: Insiders Are Selling—Should You? NATO Deal Sparks 4% Jump in Palantir Stock—What’s Next? Microsoft: A Blend of Growth and Value Amid Tariff Concerns Why NVIDIA Stock Could Soar Despite Wall Street Downgrades Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold Don’t Fear, New Highs for Fastenal Will Soon Be Here Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
